Protein biomarker indicators of neurological injury and/or disease and methods of use thereof

A method of diagnosing and treating a neurological or brain injury in a subject that has, or is suspected of having, a neurological or brain injury, the method comprising:

• (A) measuring the levels of protein biomarkers or peptide biomarkers derived therefrom in a biomarker panel comprising soluble Suppression of Tumorigenicity 2 protein (sST2), Glial Fibrillary Acidic Protein (GFAP), and Neurogranin (NRGN) (collectively, “biomarkers”) present in a biological sample taken from the subject relative to the levels of the same biomarker in respective control samples;
• (B) diagnosing a neurological or brain injury in the subject when the measured levels of one or more of the biomarkers are higher or lower in the subject's sample relative to the corresponding levels of the one or more biomarkers in the one or more respective control samples;
• and
• (C) treating the neurological or brain injury in the subject diagnosed in step (B) with an effective amount of therapy or drug.

A method of treating post-traumatic brain injury (“TBI”) seizures, post-TBI depression, post-TBI anxiety, post-TBI post-traumatic stress disorder (PTSD), post-TBI sleep disorder, post-TBI headache, post-TBI chronic pain, post-TBI oculomotor deficits, post-TBI attention and cognitive defects, and/or post-TBI balance and gait problems in a subject, the method comprising:

• (A) measuring the levels of protein biomarkers or peptide biomarkers derived therefrom in a biomarker panel comprising soluble Suppression of Tumorigenicity 2 protein (sST2), Glial Fibrillary Acidic Protein (GFAP), and Neurogranin (NRGN) (collectively, “biomarkers”) present in a biological sample taken from the subject relative to the levels of the same biomarker in respective control samples;
• (B) stratifying the risk of the patient at one or more time points for post-TBI seizures, post-TBI depression, post-TBI anxiety, post-TBI post-traumatic stress disorder (PTSD), post-TBI sleep disorder, post-TBI headache, post-TBI chronic pain, post-TBI oculomotor deficits, post-TBI attention and cognitive defects, and/or post-TBI balance and gait problems as high when the measured levels of one or more of the biomarkers are higher or lower in the subject's sample relative to the corresponding levels of the one or more biomarkers in the one or more respective control samples;
• and
• (C) administering an effective amount of therapy or drug to the patient.